Ordering Recommendation

Use to evaluate response failure to adalimumab therapy. Use to determine and adjust dosage or identify the need for change to another anti-TNF-α inhibitor.




Cell Culture/Quantitative Chemiluminescent Immunoassay/Semi-Quantitative Chemiluminescent Immunoassay




2-3 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation

Collect specimens before next adalimumab treatment.


Serum separator tube.

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)

Storage/Transport Temperature


Unacceptable Conditions

Contaminated, hemolyzed, icteric, or lipemic specimens.


After separation from cells: Ambient: 48 hours; Refrigerated: 4 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Reference Interval

Available Separately Components Reference Interval
No Adalimumab Activity Not Detected
No Adalimumab Neutralizing Antibody Not Detected

Interpretive Data

This test measures the capacity of adalimumab to neutralize TNF activity. Additionally, adalimumab neutralizing antibodies (NAb) are titered, reporting the minimal serum dilution at which blocking of adalimumab activity is no longer observed.

This test is used to evaluate secondary response failures to adalimumab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.

Circulating adalimumab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.

*AGA recommended target trough concentration for reactive monitoring of patients with active IBD on maintenance therapy is 7.5 ug/mL or greater for adalimumab (Feuerstein JD, et al. Gastroenterology. 2017;153:827-834). The AGA makes no recommendation regarding the use of routine, proactive therapeutic drug monitoring in adults with quiescent IBD treated with anti-TNF agents.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Clinical Interpretation of Adalimumab and Antibody Testing Results in the Context of Treatment Failure
Adalimumab Activity Adalimumab Neutralizing Antibody Titer Interpretation
Not Detected Not Detected Sub-therapeutic dose. A higher dosage of adalimumab or shortening the dosing interval may be appropriate.
Not Detected Detected Likely immune-mediated treatment failure. A change to another anti-TNF drug may be appropriate.
Detected - Below Target* N/A Sub-therapeutic dose. A higher dosage of adalimumab or shortening the dosing interval may be appropriate.
Detected - Above Target* N/A A change to another type of therapy (not targeting TNF) may be appropriate if patient is not responding.

Compliance Category

Laboratory Developed Test (LDT)


This test is performed pursuant to an agreement with Svar Life Sciences.

Hotline History


CPT Codes

80145; 82397


Component Test Code* Component Chart Name LOINC
2011249 Adalimumab Activity 74117-3
2011250 Adalimumab Neutralizing Antibody 92765-7
2011251 EER Adalimumab 11526-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • Humira
Adalimumab Activity and Neutralizing Antibody